Skip to main content
SpringerLink
Log in

Trabectedin

A Review of its Use in the Management of Soft Tissue Sarcoma and Ovarian Cancer

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Trabectedin (Yondelis®; ET-743) is an antineoplastic agent that was originally derived from the Caribbean marine tunicate Ecteinascidia turbinata and is now produced synthetically. It binds to the minor groove of DNA, disrupting the cell cycle and inhibiting cell proliferation. Intravenous trabectedin administered once every 3 weeks is approved as monotherapy in Europe for use in patients with advanced soft tissue sarcoma (STS) after failure of standard therapy with anthracyclines or ifosfamide, or who are unsuited to receive these agents. It also has orphan drug status in STS in the US and in ovarian cancer in the US and Europe, and is under investigation as combination therapy in patients with recurrent ovarian cancer.

In clinical trials, trabectedin showed efficacy in the treatment of patients with advanced or metastatic STS, especially those with leiomyosarcoma or liposarcoma, as well as in women with platinum-sensitive advanced or recurrent ovarian cancer. In addition, its tolerability profile was generally manageable. The introduction of trabectedin expands the currently limited range of effective treatment options for patients with advanced or metastatic STS; trabectedin also has the potential to be a beneficial treatment for advanced or recurrent ovarian cancer.

Pharmacological Properties

Trabectedin, an antineoplastic agent originally derived from the Caribbean marine tunicate Ecteinascidia turbinata that is now produced synthetically, binds to the minor groove of DNA. Unlike other minor-groove binders that bend DNA towards the site of interaction, trabectedin bends DNA towards the major groove. Although the exact mechanism of action is not clear, it is thought that interference with the transcription-coupled nucleotide excision repair pathway is an important component. In addition, trabectedin blocks the G2/M phase of the cell cycle and is a selective inhibitor of activated gene transcription.

Trabectedin has demonstrated activity in vitro and in vivo against a range of solid tumour cell lines, human xenografts and human tumour explants, including STS, ovarian, breast, prostate and renal cancers, melanoma and non-small cell lung cancer. In vitro and in vivo studies indicated that trabectedin had an additive or synergistic effect when combined with other antineoplastic agents, such as cisplatin, doxorubicin or irinotecan. Unlike many other chemotherapeutic agents used in treatment of STS, trabectedin resistance does not appear to involve MDR1 gene transcription.

Trabectedin displayed linear pharmacokinetics over a wide dose range in patients with solid tumours (including STS). However, pharmacokinetic parameters showed a large interpatient variability. The mean maximum plasma concentration after intravenous administration of trabectedin 1.5 mg/m2 as a 24-hour infusion in patients with STS was 1.04–1.34 ng/mL and the mean area under the plasma concentration-time curve was 39.9–45.5 ng · h/mL. Trabectedin is extensively distributed into tissues.

Trabectedin is predominantly metabolised via the cytochrome P450 (CYP) pathway with a lesser contribution from phase II metabolism. The cytotoxicity of trabectedin is increased when it is coadministered with CYP inhibitors, but is unchanged when the drug is coadministered with CYP inducers or phase II enzyme inhibitors. Faecal excretion predominates. Impaired hepatic function is associated with reduced total body clearance of trabectedin and may require dosage reductions.

Therapeutic Efficacy

In a randomised, nonblind, multicentre trial in chemotherapy-experienced patients with advanced or metastatic leiomyosarcoma or liposarcoma, intravenous trabectedin 1.5 mg/m2 administered over 24 hours every 3 weeks (3-weekly trabectedin) was significantly more effective than the weekly regimen in terms of the median time to disease progression (primary endpoint), as well as for the objective response rate, progression-free survival and overall survival duration. These efficacy outcomes were supported by the results of several noncomparative studies of trabectedin 1.5 mg/m2 administered over 24 hours every 3 weeks in patients with advanced or metastatic STS.

In a randomised, nonblind, multicentre study in patients with recurrent platinum-sensitive ovarian cancer, intravenous trabectedin was an effective therapy in terms of an objective response (primary endpoint), irrespective of whether the patients had received 3-weekly trabectedin 1.5 mg/m2 as a 24-hour infusion or 1.3 mg/m2 as a 3-hour infusion. Median time to progression, median duration of response and cancer antigen-125 response also support the efficacy of trabectedin in this patient group. Noncomparative studies of trabectedin in patients with advanced or recurrent platinum-sensitive or -resistant ovarian cancer established the efficacy of trabectedin in platinum-sensitive disease.

Tolerability

In clinical studies, the toxicity profile of trabectedin was largely manageable, with the majority of adverse events being grade 1 or 2 toxicities; adverse events were enerally reversible, dose or time dependent and noncumulative.

The most common severe (grade 3 or 4) treatment-emergent haematological dverse event associated with trabectedin in the randomised studies was neutropenia, hich occurred in up to half of patients who received 3-weekly trabectedin.5 mg/m2 over 24 hours or 1.3 mg/m2 over 3 hours. Most cycle delays or dose eductions were as a result of haematological toxicity, mainly neutropenia.

The most frequent severe treatment-emergent biochemical adverse event was levation of serum ALT or AST levels, which occurred in ≈50% of patients receiving 3-weekly trabectedin in the randomised studies. Nevertheless, peak ALT or AST levels resolved fully between treatment cycles and no treatment discontinuations occurred as a result of ALT or AST elevation. Other frequent treatment-emergent severe adverse events associated with trabectedin therapy included fatigue, nausea and/or vomiting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hartmann JT, Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 2005; 65(2): 167–78

    Article  PubMed  CAS  Google Scholar 

  2. Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin Oncol 2007 Apr; 34 (2 Pt 2): S1–15

    Article  PubMed  CAS  Google Scholar 

  3. American Cancer Society. Cancer facts and figures 2007 [online]. Available from URL: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf [Accessed 2007 Jul 3]

  4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf [Accessed 2007 Mar 16]

  5. Nielsen OS, Blay JY, Judson IR, et al. Metastatic soft tissue sarcoma: prognosis and treatment options. Am J Cancer 2003; 2(3): 211–21

    Article  CAS  Google Scholar 

  6. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004 Mar 1; 22(5): 890–9

    Article  PubMed  CAS  Google Scholar 

  7. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004; 54: 94–109

    Article  PubMed  Google Scholar 

  8. Clark MA, Fisher C, Judson I, et al. Soft-tissue sarcomas in adults. N Engl J Med 2005 Aug 18; 353: 701–11

    Article  PubMed  CAS  Google Scholar 

  9. Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006; 18(4): 347–53

    Article  PubMed  CAS  Google Scholar 

  10. Kasper B, Gil T, Awada A. Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? Curr Opin Oncol 2007; 19: 226–340

    Article  Google Scholar 

  11. Aletti GD, Gallenberg MM, Cliby WA, et al. Current management strategies for ovarian cancer. Mayo Clin Proc 2007 Jun; 82(6): 751–70

    PubMed  Google Scholar 

  12. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006 Jun; 107(6): 1399–410

    Article  PubMed  Google Scholar 

  13. Simmons TL, Andrianasolo E, McPhail K, et al. Marine natural products as anticancer drugs. Mol Cancer Ther 2005 Feb; 4(2): 333–42

    PubMed  CAS  Google Scholar 

  14. Simoens C, Korst AE, De Pooter CM, et al. In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. Br J Cancer 2003 Dec 15; 89(12): 2305–11

    Article  PubMed  CAS  Google Scholar 

  15. Cvetkovic RS, Figgitt DP, Plosker GL. ET-743. Drugs 2002; 62(8): 1185–92

    Article  PubMed  CAS  Google Scholar 

  16. Marco E, David-Cordonnier MH, Bailly C, et al. Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA. J Med Chem 2006 Nov 16; 49(23): 6925–9

    Article  PubMed  CAS  Google Scholar 

  17. Friedman D, Hu Z, Kolb EA, et al. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002 Jun 15; 62(12): 3377–81

    PubMed  CAS  Google Scholar 

  18. Herrero AB, Martin-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006; 66(16): 8155–62

    Article  PubMed  CAS  Google Scholar 

  19. Minuzzo M, Ceribelli M, Pitarque-Marti M, et al. Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol Pharmacol 2005 Nov; 68(5): 1496–503

    Article  PubMed  CAS  Google Scholar 

  20. Scotlandi K, Perdichizzi S, Manara MC, et al. Effectiveness of ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 2002; 8: 3893–903

    PubMed  CAS  Google Scholar 

  21. Izbicka E, Lawrence R, Raymond E, et al. In vitro antitumour activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 1998; 9: 981–7

    Article  PubMed  CAS  Google Scholar 

  22. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001 Sep; 7(9): 2908–11

    PubMed  CAS  Google Scholar 

  23. Laverdiere C, Kolb EA, Supko JG, et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003 Aug 15; 98(4): 832–40

    Article  PubMed  CAS  Google Scholar 

  24. Takahashi N, Li WW, Banerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001 Oct; 7(10): 3251–7

    PubMed  CAS  Google Scholar 

  25. D’Incalci M, Colombo T, Ubezio P, et al. The combination of Yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003; 39: 1920–6

    Article  PubMed  Google Scholar 

  26. Riccardi A, Meco D, Ubezio P, et al. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs 2005; 16(8): 811–5

    Article  PubMed  CAS  Google Scholar 

  27. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003 Aug; 52(2): 131–8

    Article  PubMed  CAS  Google Scholar 

  28. Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent Yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005 Apr 1; 65(7): 2964–71

    Article  PubMed  CAS  Google Scholar 

  29. Shao L, Kasanov J, Hornicek FJ, et al. Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. Biochem Pharmacol 2003 Dec 15; 66(12): 2381–95

    Article  PubMed  CAS  Google Scholar 

  30. Manara MC, Perdichizzi S, Serra M, et al. The molecular mechanisms responsible for resistance to ET-743 (Trabectedin; Yondelis) in the Ewing’s sarcoma cell line, TC-71. Int J Oncol 2005 Dec; 27(6): 1605–16

    PubMed  CAS  Google Scholar 

  31. Beumer JH, Buckle T, Ouwehand M, et al. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest New Drugs 2007 Feb; 25(1): 1–7

    Article  PubMed  CAS  Google Scholar 

  32. Marchini S, Marrazzo E, Bonomi R, et al. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur J Cancer 2005 Jan; 41(2): 323–33

    Article  PubMed  CAS  Google Scholar 

  33. Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat. Cancer Res 2003 Sep 15; 63(18): 5902–8

    PubMed  CAS  Google Scholar 

  34. Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002 Oct; 50(4): 309–19

    Article  PubMed  CAS  Google Scholar 

  35. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004 Apr 15; 22(8): 1480–90

    Article  PubMed  CAS  Google Scholar 

  36. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005 Aug 20; 23(24): 5484–92

    Article  PubMed  CAS  Google Scholar 

  37. van Kesteren C, Cvitkovic E, Taamma A, et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 2000 Dec; 6(12): 4725–32

    PubMed  Google Scholar 

  38. Trabectedin (Yondelis®): summary of product characteristics. Madrid, Spain: PharmaMar, 2007 Sep 17

  39. National Cancer Institute. Phase II study of ecteinascidin 743 in pediatric patients with recurrent or refractory soft tissue sarcomas or Ewing’s sarcoma family of tumors [online]. Available from URL: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=329999&version=HealthProfessional&protocolsearchid=3494068 [Accessed 2007 Sep 10]

  40. Lau L, Supko JG, Blaney S, et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children’s Oncology Group study. Clin Cancer Res 2005 Jan 15; 11 (2 Pt 1): 672–7

    PubMed  CAS  Google Scholar 

  41. Perez Ruixo JJ, Zannikos P, Hirankarn S, et al. Population pharmacokinetics of trabectedin (ET-743) in subjects with cancer [abstract no. 2030]. J Clin Oncol 2006 Jun 20; 18 (Pt 1 Suppl. 24): 86

    Google Scholar 

  42. Beumer JH, Rademaker-Lakhai JM, Rosing H, et al. Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer. Cancer Chemother Pharmacol 2007; 59: 825–37

    Article  PubMed  CAS  Google Scholar 

  43. Brandon E, Meijerman I, Klijn JS, et al. In-vitro cytotoxicity of ET-743 (trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 2005; 16: 935–43

    Article  PubMed  CAS  Google Scholar 

  44. Brandon E, Sparidans RW, Guijt K-J, et al. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectedin®), a novel marine anti-cancer drug. Invest New Drugs 2006; 24: 3–14

    Article  PubMed  CAS  Google Scholar 

  45. Salazar R, Pardo B, Majem M, et al. Phase I clinical and pharmacological trial of trabectedin in 3 hour infusion every 3 weeks in patients with advanced cancer and hepatic function disorder [abstract no. 2080]. J Clin Oncol 2006 Jun 20; 18 (Pt 1 Suppl. 24): 99

    Google Scholar 

  46. Papadopoulos KP, Chu Q, Patnaik A, et al. Phase I and pharmacokinetics study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors [abstract no. 2029]. J Clin Oncol 2006 Jun 20; 18 (Pt 1 Suppl. 24): 86

    Google Scholar 

  47. Vidal L, Garcia-Martin M, Tan S, et al. Phase I combination study of trabectedin and carboplatin in advanced solid tumours [abstract no 396P]. Ann Oncol 2004; 15 Suppl. 3: 106

    Google Scholar 

  48. Morgan JA, Le Cesne A, Chawla S, et al. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide (I) [abstract no. 10060]. Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1–5; Chicago (IL)

  49. Del Campo J, Roszak A, Ciuleanu T, et al. Phase II open label randomized study of trabectedin given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results [abstract no. 5031]. J Clin Oncol 2006 Jun 20; 18 (Pt 1 Suppl. 24): 263. Plus poster presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2–6; Atlanta (GA)

    Google Scholar 

  50. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005 Jan 20; 23(3): 576–84

    Article  PubMed  Google Scholar 

  51. McMeekin DS, Krasner C, Chan S, et al. Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma [abstract no. 5011]. J Clin Oncol 2005 Jun 1; 16 (Pt 1 Suppl. 23): 457

    Google Scholar 

  52. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005 Mar 20; 23(9): 1867–74

    Article  PubMed  CAS  Google Scholar 

  53. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595–602

    Article  PubMed  CAS  Google Scholar 

  54. PharmaMar. Enrolment completed for phase III study of Yondelis® in relapsed ovarian cancer [online]. Available from URL: http://www.pharmamar.com/en/press/news_release.cfm?newsReleaseID=167&year=2007 [Accessed 2007 Jun 19]

  55. National Cancer Institute. A study comparing the combination of Doxil® and Yondelis®, to Doxil® alone for subjects with ovarian cancer [online]. Available from URL: http://www.cancer.gov [Accessed 2007 Sep 10]

  56. World Health Organisation. WHO performance scale [online]. Available from URL: http://www.kmuh.org.tw/www/cancer/contents/Stage/Scale.pdf [Accessed 2007 May 10]

  57. Eastern Cooperative Oncology Group. ECOG performance status [online]. Available from URL: http://www.ecog.org/general/perf_stat.html [Accessed 2007 May 9]

  58. Demetri GD, Schuetze S, Le Cesne A, et al. Impact of independent review on efficacy outcomes in a randomised multicenter trial of trabectedin given by two dosing regimens in patients with progressing leiomyosarcomas or liposarcomas [abstract no O#7500]. Eur J Cancer Suppl 2007; 5(4): 401

    Article  Google Scholar 

  59. Le Cesne A, von Mehren M, Chawla S, et al. Assessing the clinical impact of trabectedin in patients with leiomyosarcomas or liposarcomas progressing despite prior conventional chemotherapy: clinical benefit rate, growth modulation index and tumor variation as parameters of treatment effect in a randomised international trial of two trabectedin dosing regimens [abstract no P#7512]. Eur J Cancer Suppl 2007; 5(4): 405

    Article  Google Scholar 

  60. World Health Organization. WHO handbook for reporting results of cancer treatment [publication no. 48]. Geneva: WHO, 1979

    Google Scholar 

  61. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000 Feb 2; 92(3): 205–16

    Article  PubMed  CAS  Google Scholar 

  62. Chawla S, Casali PG, von Mehren M, et al. Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced/ metastatic liposarcoma or leiomyosarcoma progressing despite prior treatment with at least anthracycline and ifosfamide [abstract no P#7517]. Eur J Cancer Suppl 2007; 5(4): 407

    Article  Google Scholar 

  63. Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006 Jul; 42(10): 1484–90

    Article  PubMed  CAS  Google Scholar 

  64. PharmaMar. The European Commission authorizes Yondelis® commercialization for soft tissue sarcoma [online]. Available from URL: http://www.pharmamar.com/en/press/news_release.cfm?newsReleaseID=173&year=2007 [Accessed 2007 Sep 20]

  65. Goldberg BR. Soft tissue sarcoma: an overview. Orthop Nurs 2007; 26(1): 4–11

    Article  PubMed  Google Scholar 

  66. European Society for Medical Oncology. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007; 2 Suppl. 18: ii74–6

    Google Scholar 

  67. Blay J-Y, Le Cesne A, Verweij J, et al. A phase II study of ET-743/trabectedin (‘Yondelis’) for patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2004; 40: 1327–31

    Article  PubMed  CAS  Google Scholar 

  68. Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 28: 543–9

    Article  Google Scholar 

  69. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66

    Article  PubMed  Google Scholar 

  70. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf [Accessed 2007 Jul 3]

  71. European Society for Medical Oncology. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007 Apr; 2 Suppl. 18: ii12–4

    Google Scholar 

  72. Fujiwara K, Armstrong D, Morgan M, et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 2007; 17: 1–20

    Article  PubMed  CAS  Google Scholar 

  73. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006 Jan 5; 354: 34–43

    Article  PubMed  CAS  Google Scholar 

  74. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003 Jun 21; 361(9375): 2099–106

    Article  PubMed  CAS  Google Scholar 

  75. Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 2006 Apr; 33 (2 Suppl. 6): 12–6

    Article  Google Scholar 

  76. Gurtler JS, Goldstein L, Delprete S, et al. Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens [abstract no. 625]. J Clin Oncol 2005 Jun 1; 23 (Pt 1 Suppl. 16): 34

    Google Scholar 

  77. Zelek L, Yovine A, Brain E, et al. A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006; 94(11): 1610–4

    Article  PubMed  CAS  Google Scholar 

  78. PharmaMar. PharmaMar announces the initiation of a randomized phase II trial of Yondelis® in breast cancer [online]. Available from URL: http://www.pharmamar.com/en/press/ news_release.cfm?newsReleaseID=163&year=2007 [Accessed 2007 Sep 10]

  79. McMeekin DS, Manikas G, Crispens M, et al. A phase II study of trabectedin (ET-743) as a second line therapy in patients with persistent or recurrent endometrial carcinoma [abstract no 5086]. J Clin Oncol 2004 Jul 15; 22 Suppl. 14: 470

    Google Scholar 

  80. Michaelson MD, Gilligan T, Oh W. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma [abstract no. 4517]. J Clin Oncol 2005 Jun 1; 2 (Pt 1 Suppl. 16): 382

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ∣ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Natalie J. Carter & Susan J. Keam

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Natalie J. Carter & Susan J. Keam

Authors
  1. Natalie J. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Natalie J. Carter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carter, N.J., Keam, S.J. Trabectedin. Drugs 67, 2257–2276 (2007). https://doi.org/10.2165/00003495-200767150-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767150-00009

Keywords

Search

Navigation